Nipah Virus Vaccine Trial: Unlocking Hope Against a Deadly Disease

World's first Phase II trial for Nipah vaccine underway in Bangladesh

Apr. 12, 2026 at 5:06am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image showing the detailed internal structure of a microscopic virus particle, with its intricate shapes and forms glowing against a dark background, conveying the complex challenge of developing a vaccine for this deadly disease.An X-ray view of the Nipah virus particle, a deadly pathogen that has the potential to spark global health crises, yet remains a priority for vaccine research and development.Union Today

A groundbreaking development in the fight against Nipah virus has just taken place! The world's first Phase II vaccine trial for this deadly disease is now underway in Bangladesh. Led by the Oxford Vaccine Group in partnership with the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), and funded by the Coalition for Epidemic Preparedness Innovations (CEPI), this trial aims to assess the safety and immune response of a promising vaccine candidate, ChAdOx1 NipahB.

Why it matters

Nipah virus, a member of the paramyxovirus family, has the potential to cause devastating pandemics. Recognized by the World Health Organization as a priority for research, Nipah virus has a high fatality rate, with up to 75% of cases resulting in death. This trial is a crucial step towards developing a much-needed vaccine to combat this deadly disease.

The details

The trial commenced earlier this month and will involve 306 healthy volunteers aged 18 to 55. This is the first Phase II trial for a Nipah virus vaccine, as the development of vaccines is a long and complex process often taking years or even decades. Despite the urgency and potential for a global health crisis, this is just one step on a long journey towards a safe and effective vaccine.

  • The trial commenced earlier this month (April 2026).
  • The trial will involve 306 healthy volunteers aged 18 to 55.

The players

Oxford Vaccine Group

A leading vaccine research group based at the University of Oxford, UK.

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

A Bangladeshi research organization that is partnering on the Nipah vaccine trial.

Coalition for Epidemic Preparedness Innovations (CEPI)

An international organization that is funding the Nipah vaccine trial.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

The development of a Nipah virus vaccine is a critical global health priority, as this deadly disease has the potential to cause widespread devastation. While this trial represents an important step forward, it highlights the long and complex process of vaccine development, underscoring the need for continued research, funding, and international collaboration to combat this threat.